Support      Solutions        Blog        News       Contact 
DOWNLOAD   /   DISCOVER  /   TUTORIALS   /   VIDEOS   /   STORE   /   ABOUT
Post-hoc Statistical Power Simulations for BioNTech-Pfizer Vaccine Trial to Evaluate Survival (failure) Differences at 21 and 90 days
Post-hoc Statistical Power Simulations for BioNTech-Pfizer Vaccine Trial to Evaluate Survival (failure) Differences at 21 and 90 days
Leif Peterson - December 17, 2020
Reference: Fernando P. Polack, M.D., Stephen J. Thomas, M.D., Nicholas Kitchin, M.D., Judith Absalon, M.D., Alejandra Gurtman, M.D., Stephen Lockhart, D.M., John L. Perez, M.D., Gonzalo Pérez Marc, M.D., Edson D. Moreira, M.D., Cristiano Zerbini, M.D., Ruth Bailey, B.Sc., Kena A. Swanson, Ph.D., Satrajit Roychoudhury, Ph.D., Kenneth Koury, Ph.D., Ping Li, Ph.D., Warren V. Kalina, Ph.D., David Cooper, Ph.D., Robert W. Frenck, Jr., M.D., Laura L. Hammitt, M.D., Özlem Türeci, M.D., Haylene Nell, M.D., Axel Schaefer, M.D., Serhat Ünal, M.D., Dina B. Tresnan, D.V.M., Ph.D., Susan Mather, M.D., Philip R. Dormitzer, M.D., Ph.D., Uğur Şahin, M.D., Kathrin U. Jansen, Ph.D., and William C. Gruber, M.D.   Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.  New England Journal of Medicine.   E-pub ahead of print, Dec. 10, 2020.  https://www.nejm.org/doi/10.1056/NEJMoa2034577
Results